# PCOS, irregular periods and GLP-1 medicines: different goals of care

How GLP-1 weight management fits alongside PCOS assessment, glucose testing and pregnancy planning.

Canonical: https://velri.co/blog/pcos-irregular-cycles-glp1-metabolic-markers-jordan
Publisher: Velri (https://velri.co/about)
Published: 2026-06-19
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

GLP-1 medicines may be considered for weight management in some adults with PCOS. That is one part of care: irregular periods, metabolic risk and pregnancy plans each need attention. The international PCOS guideline includes semaglutide as a possible weight-management option under general eligibility guidance. [1]

## Why cycle history and glucose testing both matter

PCOS raises the risk of impaired glucose regulation and type 2 diabetes across body sizes. The guideline recommends assessing glucose status at diagnosis and identifies an oral glucose tolerance test as the most accurate option. Fasting glucose or A1c may be considered when that test cannot be performed, with lower accuracy in this setting. [1]

The guideline does not recommend routinely available insulin assays for routine PCOS care. [1]

Long gaps between periods also deserve their own assessment. Long-standing untreated absence of periods can add to endometrial risk in PCOS, so a weight change alone does not settle the cycle question. [1]

## What a weight-management prescription involves

Eligibility depends on weight-related health conditions and the specific medicine, along with medical history, other medications, possible side effects and cost. Weight medicines are used alongside nutrition and activity support; responses differ, and ongoing use may be needed to maintain benefit. [2]

For someone with PCOS, that discussion also includes pregnancy intentions. The guideline calls for effective contraception when pregnancy is possible during GLP-1 use because pregnancy safety data are lacking. [1]

These are separate goals worth naming clearly: improving metabolic health, managing weight, addressing infrequent periods, or planning pregnancy. A treatment chosen for one goal may leave another unfinished.

## Sources
[1] Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome (2023) | American Society for Reproductive Medicine | ASRM (2023). https://www.asrm.org/practice-guidance/practice-committee-documents/recommendations-from-the-2023-international-evidence-based-guideline-for-the-assessment-and-management-of-polyendocrine-metabolic-ovarian-syndrome-2023/
[2] Prescription Medications to Treat Overweight & Obesity - NIDDK (2025). https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support